Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2007-05-21
2010-10-19
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S007210, C435S391000, C435S069100
Reexamination Certificate
active
07815895
ABSTRACT:
A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver.
REFERENCES:
Eisen S et al. Inhibitory effects on intake of cholecystokinin-8 and cholecystokinin-33 in rats with hepatic proper or common hepatic branch vagal innervation. Am J Physiol Regul Integr Comp Physiol. 2005; 289:R456-R462.
Horn CC et al. Role of vagal afferent innervation in feeding and brain Fos expression produced by metabolic inhibitors. Brain Res. 2001; 919:198-206.
Kim S et al. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene, Sep. 2004; 340(1):99-109.
Nakano R et al. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol. Jun. 2006; 72:42-52.
Flier, J.S., “Obesity Wars: Molecular Progress Confronts an Expanding Epidemic”, Cell, vol. 116, Jan. 23, 2004, pp. 337-350.
Friedman, J.M. et al., “Leptin and the regulation of body weight in mammals”, Nature, vol. 395, Oct. 22, 1998, pp. 763-770.
Minokoshi, Yasuhiko et al., “Tissue-specfic Ablation of the GLUT4 Glucose Transporter or the Insulin Receptor Challenges Assumptions about Insulin Action and Glucose Homeostasis”, The Journal of Biological Chemistry, vol. 278, Sep. 5, 2003, pp. 33609-33612.
Kitamura, Tadahiro et al., “Insulin Receptor Knockout Mice”, Annual Review of Physiology, vol. 65, 2003, pp. 313-332.
An, Jie et al., “Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance”, Nature Medicine, Feb. 8, 2004, pp. 1-7.
Yamada, Tetsuya et al., “Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: Neuronal involvement in food-intake regulation”, Cell Metabolism, vol. 3, Mar. 2006, pp. 223-229.
Gavrilova, Oksana et al., “Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass”, The Journal of Biological Chemistry, vol. 276, Sep. 5, 2003, pp. 34268-34276.
Bocher, Virginie et al., “PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism”, Annals of the New York Academy of Sciences, vol. 967, 2002, pp. 7-18.
Fajas, Lluis et al., “The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene”, The Journal of Biological Chemistry, vol. 272, No. 30, Jul. 25, 1997, pp. 18779-18789.
Burant, Charles F. et al., “Troglitazone Action is Independent of Adipose Tissue”, The Journal of Clinical Investigation, vol. 100, No. 11, Dec. 1997, pp. 2900-2908.
Chao, Lily et al., “Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones”, The Journal of Clinical Investigation, vol. 106, No. 10, Nov. 2000, pp. 1221-1228.
Rahimian, Roshanak et al., “Hepatic over-expression of peroxisome proliferator activated receptor γ2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus”, Molecular and Cellular Biochemistry, vol. 224, Apr. 9, 2001, pp. 29-37.
Matsusue, Kimihiko et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes”, The Journal of Clinical Investigation, vol. 111, No. 5, Mar. 2003, pp. 737-747.
Ishigaki, Yasushi et al., “Dissipating Excess Energy Stored in the Liver is a Potential Treatment Strategy for Diabetes Associated With Obesity”, Perspectives in Diabetes, vol. 54, Feb. 2005, pp. 322-332.
Hosono, Tetsuji et al., “RNA interference of PPARγ using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells”, Gene Section Functional Genomics, vol. 348, 2005, pp. 157-165.
Katagiri, Hideki et al., “Overexpression of Catalytic Subunit P110α of Phosphatidylinositol 3-Kinase Increases Glucose Transport Activity with Translocation of Glucose Transporters in 3T3-L1 Adipocytes”, The Journal of Biological Chemistry, vol. 271, No. 29, Jul. 19, 1996, pp. 16987-16990.
Kanegae, Yumi et al., “Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase”, Nucleic Acids Research, vol. 23, No. 19, pp. 3816-3821.
Ikemoto, Shinji et al., “High fat diet-induced hyperglycemia: Prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice”, Proceedings of the National Academy of Sciences of the United States of America, vol. 92, Apr. 1995, pp. 3096-3099.
Ono, Hiraku et al., “Hepatic Akt Activation Induces Marked Hypoglycemia, Hepatomegaly, and Hypertriglyceridemia With Sterol Regulatory Element Binding Protein Involvement”, Diabetes, vol. 52, Dec. 2003, pp. 2905-2913.
Ogihara, Takehide et al., “Insulin Receptor Substrate (IRS)-2 Is Dephosphorylated More Rapidly than IRS-1 via Its Association with Phosphatidylinositol 3-Kinase in Skeletal Muscle Cells”, The Journal of Biological Chemistry, vol. 272, No. 19, May 9, 1997, pp. 12868-12873.
Jones, Julie R. et al., “Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance”, Proceedings of the National Academy of Sciences of the United States of America, vol. 102, No. 17, Apr. 26, 2005, pp. 6207-6212.
Nashat, Amir H. et al., “Temporal Characteristics of Activation, Deactivation, and Restimulation of Signal Transduction following Depolarization in the Pheochromocytoma Cell Line PC12”, Molecular and Cellular Biology, vol. 23, No. 14, Jul. 2003, pp. 4788-4795.
Katagiri Hideki
Oka Yoshitomo
Uno Kenji
Yamada Tetsuya
Ballard Kimberly A.
Barnes & Thornburg LLP
Kemmerer Elizabeth C.
Tohoku University
LandOfFree
Method for activating efferent sympathetic nerves... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for activating efferent sympathetic nerves..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for activating efferent sympathetic nerves... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226496